Courtallam ima gynec onco ppt
-
Upload
dr-rajkumar-r -
Category
Health & Medicine
-
view
378 -
download
1
description
Transcript of Courtallam ima gynec onco ppt
ROLE OF CHEMOTHERAPY IN GYNAEC MALIGNANCIES
DR. R. RAJKUMAR M.D., D.M.
OVARIAN CANCER
Leading cause of death from gynecologic cancer 75% present in advanced stage Improvement in 5yr survival – 36% in 1977 39% in 1986 45% in 2002 More effective chemotherapy options Surgical techniques
OVARIAN CANCER – CLINICAL FINDINGS
Usual features : Abdomino –pelvic mass, ascites, left supraclavicular
lymph node Unusual presentations: Right supraclavicular or axillary lymph nodes with
abdominal mass Isolated pleural effusion Isolated ascites without any ovarian mass
OVARIAN CANCER - EVALUATION
Detailed history and clinical exam Pelvic exam including per rectal exam to assess POD
- EUA Endometrial biopsy in selected cases Complete blood counts Renal function tests Liver function tests Tumor markers Chest x ray & other imaging studies Genetic counseling
OVARIAN CANCER - EVALUATION Tumor markers: CA 125 –most commonly elevated in 80% of serous tumors not elevated in 50% of early stage tumors, mucinous and clear
cell carcinomas Not a reliable diagnostic test Post operatively ca125 levels –sensitive –to monitor response
to chemo Normalization after 3 cycles –favorable outcome Nadir <10u/ml – favorable Useful in follow up for detecting recurrence CEA , CA 19-9 - mucinous tumors & in krukenbergs tumor
OVARIAN CANCER – TUMOR MARKERS
Sr.VEGF levels HE4 (human epididymis 4)-WFDC gene product MCS-F in serum & ascitic fluid Proteomic spectral analysis of serum SELDI-TOF –MS : Surface enhanced laser desorption
and ionization time of flight MS
OVARIAN CANCER - IMAGING
USG abdomen with colour doppler study –transvaginal sonography
Complex mass with increased vascularity Ascites Enlarged para aortic nodal masses Omental and peritoneal deposits larger than 1cm Matted bowel loops
Ultrasonography &Colour Doppler
OVARIAN CANCER - IMAGING
CT SCAN abdomen & pelvis:
Extent of disease in upper abdomen Helps to decide on primary surgery or neoadjuvant chemotherapy Attachment of omentum to splenic hilum Disease/tumor nodules >2cm in mesentery, liver surface or parenchyma,
diaphragm, gall bladder fossa, suprarenal para aortic nodes Pulmonary or pleural nodules
CT Scan
OVARIAN CANCER - IMAGING
MRI abdomen – not superior to CTscan except in pregnant women where USG is inconclusive
PET-CT scan : not for diagnosis Useful in rec.disease with isolated CA125 elevation
OVARIAN CANCER - INVESTIGATIONS
UPPER GI SCOPY& COLONOSCOPY – NOT INDICATED ROUTINELY
Symptoms s/o gastric disease or lower GI symptoms or fecal occult blood positive
4% have associated GI malignancy
Mammography Genetic counseling in pts with positive family history
EPITHELIAL OVARIAN CANCER
DIAGNOSISSymptoms
Clinical Examination
Investigations
Ca125 Imaging
USG Colour Doppler CT/MRI
FNAC contraindicated
OVARIAN CANCER STAGING
Stage I - Limited to ovaries
A. Unilateral ovary
B. Bilateral ovaries
C. Positive cytology
Stage II - Limited to pelvis
A. Extends to uterus or tubes
B. other pelvic organs
C. Positive cytology
Stage III – Spread to upper abdomen or regional lymph nodes
A. Microscopic spread
B. Macroscopic < 2 cm
C. Macroscopic > 2 cm
Stage IV - Spread outside peritoneum, pleura or parenchymalliver metastases
OVARIAN CANCER FIGO STAGING SYSTEM
Stage Description Incidence Survival I Confined to ovaries 20% 73%
II Confined to pelvis 5% 45%
III Confined to abdomen/ 58% 21%lymph nodes
IV Distant metastases 17% <5%
Jelic S, et al. Program and abstracts of the 27th Congress of the European Society for Medical Oncology; 2002; Nice, France.
Mocharnuk R. Medscape Web site. http://www.medscape.com/viewarticle/444134. Accessed May 2, 2007.
FIGO = International Federation of Gynecology and Obstetrics
HOW TO PROCEED AFTER INVESTIGATIONS ?
Decision to proceed directly to surgery is a clinical one – in advanced stage :
based on extent of disease
Performance status
Nutritional status
Comorbid illness
HOW TO PROCEED AFTER INVESTIGATIONS?
Operable tumors – laparotomy and proceed
Avoid percutaneous FNA of localised masses or complex cysts – upstage disease
WHO NEEDS NEOADJUVANT CHEMOTHERAPY?
Presence of gross ascites,
huge fixed pelvi-abdominal mass,
nodules in POD PS III-IV
Supraclavicular nodes
Pleural effusion – bilateral
USG abdomen showing
extensive peritoneal,omental deposits and liver sec, bilateral pleural effusion
CT SCAN FINDINGS
Diffuse peritoneal thickening(DPT) >4mm – involving atleast 2 of the 5 areas
lateral colic gutters Lateral conal fascia Anterial abdominal wall Diaphragm and splenic peritoneal reflection
Sean C.Dowdy et al, CANCER - 2004
FOR NEOADJUVANT CHEMOTHERAPY
Cytologic evidence of malignancy – ascitic fluid
FNA of the mass ( transvaginal –preferably)
Laparoscopy before NACT:
- to assess disease extent and for biopsy in cases where repeated cytology is negative for malignancy
OVARIAN CANCER SURGICAL DEBULKING AND STAGING
Exploration
Washings/Ascites
(Staging)
TAH/BSO
Biopsies(Staging)
Goals (Debulking)•Assessment of extent of disease
•Optimal tumor reduction
TAH = total abdominal hysterectomy
BSO = bilateral salphingo-oophorectomy
Cytoreductive Surgery
Goal is elimination of all tumor• No gross residual (microscopic)• Optimal (<1 cm)• Suboptimal (>1 cm)
Operative Technique• Resection of urinary or intestinal tract
Surgical Outcomes• Optimal in ~75% of cases• Does it matter?
Does Cytoreduction Matter?
Optimal Suboptimal
Response Rate
Clinical CR 95% 75%
Pathologic CR 50% 25%
Progression free interval (mo) 34 13
Survival (mo) 50 36
10-yr survival 35% 15%
PROGNOSTIC FACTORS
Volume of residual disease after surgery Stage Histologic subtype Histologic grade Performance status Age Ovarian cancer prognostic profile(OCPP) Chemotherapy response profile (CRP) Gene expression profiling
PRIMARY TREATMENT OF OVARIAN CANCER
1995 1997 1999
Cyclophosphamide + Cisplatin
STANDARD OF CARE
GOG 111 establishes Taxol-CDDPas standard 1st line
2001
GOG 158 shows Taxol-carboplatin = Taxol-CDDP, with improved toxicity and QoL
GOG 178 demonstrates improved DFS with longer duration of maintenance Taxol – No
data on overall survival
GOG 172 confirms IP therapy leads to a survival
advantage compared with IVNEW STANDARD OF CARE?
SWOG 8501 demonstrates improved survival with IP therapy
2003 2005 2008
GOG 182 demonstrates no survival advantage to triplet or sequential
doublet therapy
FIRST-LINE THERAPY – Standard Treatment Options
Platinum + Taxane Chemotherapy(Carboplatin + Paclitaxel)
Surgery with maximum cytoreduction effort <1cm
residual disease
CHEMOTHERAPY• Standard front-line chemotherapy today is
carboplatin, AUC 6 to 7.5, paclitaxel 175 mg/m2 every 21 days for 6 cycles
• Result of several studies over last decade– GOG 1111 and OV 102 - paclitaxel/cisplatin
vs cyclophosphamide/cisplatin
– GOG 1583 and AGO OVAR-34 - carboplatin instead of cisplatin
1. McGuire WP, et al. N Engl J Med. 1996;334(1):1-6.2. Piccart MJ, et al. J Natl Cancer Inst. 2000;92(9):699-708. 3. Ozols RF, et al. J Clin Oncol. 2003;21(17):3194-3200.4. du Bois AD, et al. J Natl Cancer Inst. 2003;95(17):1320-1329.
GOG = Gynecologic Oncology GroupAGO = ArbeitsgemeinschaftGynaekologische Onkologie
The Role of Paclitaxel in First-line Therapy for Ovarian Carcinoma
Study # Pts RegimenMedian PFS
(mo)Median OS
(mo)
GOG 1321
377III suboptimal-IV
Cisplatin/Paclitaxel (24 h) x 6
14.1 26.3
Cisplatin 100 mg/m2 x 6 16.4 30.2Paclitaxel 200 mg/m2 (24 h)* 10.8 25.9
ICON32
2074I-IV
Carboplatin/Paclitaxel (3 h)
17.3 36.1
Carboplatin or CAP 16.1 35.4
CAP = cyclophosphamide, doxorubicin, cisplatinGOG = Gynecologic Oncology GroupICON = International Collaborative Ovarian Neoplasm Group OS = overall survivalPFS = progression-free survival
1. Muggia FM, et al. J Clin Oncol. 2000;18(1):106-115. 2. International Collaborative Ovarian Neoplasm Group. Lancet. 2002;360(9332):505-515.
*CR/PR rates on paclitaxel monotherapy (42%) vs cisplatin regimens (67%), P <.001
OVARIAN CARCINOMA: CLINICAL COURSE
Symptoms
Diagnosis
Chemotherapy #1
StagingPrimary cytoreduction
Interval Cytoreduction
Progression
Chemo #2 Chemo #3+
SupportiveCare
Death
Consolidation/Maintenance
Cure
SecondaryCytoreductionSecond-Look
EPITHELIAL OVARIAN CANCERPLAN OF MANAGEMENT
Resectable
Primary cytoreductive surgery (Max)
Chemo 6 cycles
Unresectable
Chemo 3 cycles
Interval cytoreductive Surgery (Max)
Chemo 3 cycles
Stage III/IV
CHEMOTHERAPY – EARLY STAGE DISEASE
High risk early stage: stage I, gr III, Ic,any stage II
Stage Ia,Ib –gr I & II can be observed
ICON I(International Collborative Ovarian Neoplasm Trial I) &
ACTION (Adjuvant Chemotherapy in Ovarian Neoplasm Trial) –chemo improves progression free & OS in high risk early stage disease(925 pts – os – superior for platinum based chemo
GOG study -3 vs 6 cycles – 33% reduction in risk of rec in high risk disease who received 6cycles of chemo
Patients with suboptimal surgery benefit from platinum based chemo
Chemotherapy in advanced stage
GOG 111: paclitaxel+cisplatin superior to cisplatin + cyclophosphamide
RR 73% vs 60%
Median PFS 18 vs 13mo
Median os 38mo vs 24mo p<001
60mo of follow up – 20% reduct. In risk of progression & 34% reduction in risk of death
OV10,ICON 3
GOG 132 –sequential administration of pacli or cisplatin is therapeutically equivalent
Chemotherapy in advanced stage
GOG 158,AGO,NETHERLANDS-DENMARK: Carboplatin+paclitaxel vs cisplatin +paclitaxel is equivalent – PFS &OS
Carbo+paclitaxel – preferred – favorable toxicity profile
Reduced emesis,neutropenia,nephrotoxicity
Short infusion time
Marginal PS,Comorbid medical condition – start with single agent carboplatin – add paclitaxel later
No benefit for 12 vs 6 cycles
No benefit for addition of 3rd cytotoxic agent – PLD,EPI,TOPO,GEM
Addition of bevacizumab
Interventions to Mortality?
Time
Dis
ea
se V
olu
me
Prevention
Screening
Current point of diagnosis and initiation of treatment
Prevention– Pedigree Analysis– Medical: Oral Contraceptives– Surgical: Risk-Reducing Oophorectomy
Screening– Pelvic Examination– Ultrasonography– CA125 and other (OvaSure) Serum Testing– Proteomics (OvaCheckTM)
Interventions to Mortality?
NIH Consensus Development Panel
“…there is no evidence available yet
that the current screening modalities
of CA 125 and ultrasonography can
be effectively used for widespread
screening to reduce mortality from
ovarian cancer…”
Screening – US and CA 125
Goals of Treatment:Relapsed Ovarian Cancer
• Prolong Survival
• Delay Time to Progression
• Control Disease-Related Symptoms
• Minimize Treatment-Related Symptoms
• Maintain or Improve Quality of Life
Surveillance Options for Ovarian Cancer Patients in Remission• Second-look laparotomy• Physical examination
– Include pelvic examination• CA-125• Imaging
– CT scan– MRI?– PET scan?
CT = computed tomographyMRI = magnetic resonance imaging PET = positron emission tomography
Ovarian Cancer:How is Relapse Defined?
• Continuous rise in CA-125• CA-125 above 100• Radiographic recurrence• Symptomatic recurrence• Physical examination findings• Combination of above
Effect of Platinum-Free Intervalon Response Rate% Response to Second-line
Platinum Therapy
Platinum-Free Interval (mos) Markman Gore Blackledge
0-617%
10%
7-12 27% 29%
13-1833% 27%
63%
19-24 94%
>24 59% 57%
Non-Platinum Therapy
15%
20%
30%
30%
Markman M, et al. J Clin Oncol. 1991;9(3):389-393. Gore ME, et al. Gynecol Oncol. 1990;36:207-211.Blackledge G, et al. Br J Cancer. 1989;59:650-653.
Refractory
PRI
MARY
TREATMENT
Resistant
Sensitive
0 3 6 12 18 24Months
“Very Sensitive”
Ovarian Cancer at First RelapseDefinition of Sensitivity
Defined as measurable recurrence, not biochemical (CA-125) recurrence
Active Agents in Ovarian CancerFDA approved
Altretamine Carboplatin Cisplatin
Gemcitabine/Carboplatin
Paclitaxel Pegylated liposomal doxorubicin
Topotecan
Not FDA approved, compendium listedChlorambucil Cyclophosphamide Docetaxel
Doxorubicin Epirubicin Etoposide
5-FU/LV Gemcitabine Ifosfamide
Irinotecan Melphalan Methotrexate
Thiotepa Vinorelbine
Not FDA approved, not compendium listedAromatase inhibitors Bevacizumab Pemetrexed
Tamoxifen
Secondary Cytoreduction
• Controversial • Inconsistent definitions• Benefit appears confined
to patients likely to respond to additional chemo:
• >12 month PFI• Isolated site of
recurrence• Disease
completely resectable Kidney
Resected LiverDiaphragm
Kidney
Vena Cava
Tumor Mass
Renal Vein
PFI = progression-free interval
Advanced Ovarian Cancer
cisplatin paclitaxelmulti-drug Alkeran
Median Survival: 1975 - 2005
IP therapy
(optimal)(optimal)
months
12 1424
3752
5766
0
20
40
60
80
1975 1983 1986 1996 1998 2003 2005
The tumor extends to the pelvic wall and/or involves lower third of the vagina and or causes hydronephrosis or non-functioning kidney **
Stage IIIA: Tumor involves lower third of the vagina, with no extension to the pelvic wallStage IIIB: Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney
The carcinoma is strictly confined to the cervix(extension to the corpus would be disregarded)
Stage IA: Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion ≤5 mm and largest extension ≤7 mmStage IA1: Measured stromal invasion of ≤3.0 mm in depth and extension of ≤7.0 mm.Stage IA2: Measured stromal invasion of >3.0 mm and ≤5.0 mm with an extension of not >7.0 mm
Stage IB: Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA*
Stage IB1: Clinically visible lesion ≤4.0 cm in greatest dimension Stage IB2: Clinically visible lesion >4.0 cm in greatest dimension
The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum.A bullous edema, as such, does not permit a case to be allotted to Stage IV
Stage IVA: Spread of the growth to adjacent organs. Stage IVB: Spread to distant organs.
Stage II
Stage I
FIGO staging system, 2009
Cevical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina
Stage IIA: Without parametrial invasionStage IIA1: Clinically visible lesion ≤4.0 cm in greatest dimensionStage IIA2: Clinically visible lesion >4 cm in greatest dimension
Stage IIB: With obvious parametrial invasion
Stage III
Stage IV
*All macroscopically visible lesions—even with superficial invasion—are allotted to stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal extension of not >7.00 mm. Depth of invasion should not be >5.00 mm taken from the base of the epithelium of the original tissue—superficial or glandular. The depth of invasion should always be reported in mm, even in those cases with “early (minimal) stromal invasion” (~1 mm). The involvement of vascular/lymphatic spaces should not change the stage allotment.** On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to another cause.
Diagnosis is based on conization!
Recommended work-up• Vaginal and rectal examination, exfoliative cytology (Papanicolaou smear), colposcopy, biopsy and/or endocervical curettage (ECC), conization or Loop electrosurgical procedure (LEEP) • Histopathological finding with all standard tumor parameters• Laboratory analyses: WBC, biochemical analyses• Imaging: Chest X-ray, pelvic and abdominal ulstrasound
ConizationNecessary HP parameters:2• Depth of invasion• Width of the tumor• Tumor differentiaion• Lympho-vascular space invasion (LVSI)• Resection margins
Margins and/orECC positive for dysplasia
Margins clearECC negative
Stage Ia1LVSI negative
•Stage Ia1 with extensive LVSI Stage Ia2
• Repeated conisation• Modified radical hysterectomy (type B6) if re-conisation is not possible± pelvic lymphadenectomy
Conization if preservation of fertility is desiredorSimple (extrafascial, type A6) hysterectomy with or without salpingoophorectomy
Conization or radical trachelectomy if preservation of fertility is desiredorModified radical hysterectomy (type B6)andPelvic lymphadenectomy
Recommended follow-upEvery 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination, including cytology and colposcopy, should be performed depending on symptoms, local findings and general condition of the patient
Cervical cancerFIGO Stage I a
Microinvasive carcinoma (invasion ≤ 5 mm)
Recommended work-upNeccessary investigations:• Vaginal and rectal examination, colposcopy, biopsy and/or endocervical curettage (ECC); conization or loop electrosurgical procedure (LEEP) if needed for definitive diagnosis• Histopathological finding with all standard tumor parameters• Laboratory analyses: WBC, biochemical analyses including check for renal function and Hb• Imaging: Chest X-ray, abdominal and pelvic ultrasound (size and position of the tumor and tumor volume/cervix ratio)Optional investigations:Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should be confimed histologically
Radical surgery
• Uterus with paracervical tissues and upper part of vagina (radical, type C6 hysterectomy) + pelvic lymphadenectomyor• Entire cervix with paracervical tissues (radical trachelectomy) if fertility is desired + pelvic lymphadenectomyor• Upper part of vaginal cuf, paracervical tissues + pelvic lymphnodes in case of previous simple hysterectomy * At least 2 cm distance from the resection margins is desirable ** In premenopausal women ovaries can be retained; if so tranposition is advised.*** For the desision of further management, all neccesary histopathologic parameters4 should be requested
Chemo-radiation
Neoadjuvant chemotherapy followed by radiation or surgery is an option for locally advanced tumors (Ib2 and IIa2) but awaits confirmatory evidence from controlled clinical trials.
Recommended follow-upEvery 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination should be performed depending on symptoms, local findings and general condition of the patient
• Positive resection margins• Involvement of parametria• Residual tumor• Multiple positive nodes (>3)
• Positive nodes (1-3)• Poorly differentiated or undifferentiated tumor (G3)• LVSI present• Primary tumor (tumor-cervix volume) >3 cm• Endocervical invasion (barrel shaped cervix)• Inadequate surgery• Insufficient HP (if report of all necessary parts is missing)
• Medical contra-indications for surgery• Ib2/IIa2 tumors in selected cases• Anterior vaginal extension• Invasive cancer after simple hysterectomy• Choice of the patient
ConcomitantChemo-radiation
Radiation± Chemotherapy
Radiation± ChemotherapyFollow up
Negative nodes
GOG score**consider using GOG score as a guide for adjuvant treatment5
Low risk(GOG score < 120)
Low risk(GOG score < 120)
or
Cervical cancerFIGO Stage Ib - IIa
Squamocellular, Adenocarcinoma, Adenosquamous
Recommended work-up• Vaginal and rectal examination, biopsy or endocervical curettage (ECC)• Histopathological finding with all standard tumor parameters• Laboratory analyses: WBC, biochemical analyses including check for renal function and Hb • Imaging: Chest X-ray, abdominal and pelvic ultrasound• Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should be confimed histologically
Recommended follow-upEvery 3 months after completed therapy; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination should be performed depending on symptoms, local findings and general condition of the patient
Pelvic MRI andAbdominal CT
Paraaortic nodes (PALN) negative(=not enlarged)
Pelvic or paraaortic nodes (PALN) positive (enlarged ≥2 cm))
Pelvic (± paraaortic) radiation+ brachytherapy+ concomitant chemotherapy
CT of the lungs & mediastinum
CT negative CT positive
Pelvic radiation (with paraaortic if PALN are positive) + brachytherapy + concomitant chemotherapy
* Consider: • resection of adnexal mass and/or extraperitoneal resection of enlarged nodes • Sequential chemoth and Concomitant ChemoRadioTherapy /External Beam RadioTherapy (CCRT/EBRT)
Palliative pelvic RT± Palliative chemotherapy
*Stage IVa• with vesicovaginal fistula: if pelvic, abdominal and chest imaging exclude distant metastases primary pelvic exenteration can be considered• NACT may be offered to large bulky tumors to downsize tumor prior to CCRT
Cervical cancerFIGO stage IIb- IV
Recommended work-up•• Vaginal and rectal examination, biopsy - histopathological confirmation of recurrence• Laboratory analyses: WBC, biochemical analyses including check for renal function and Hb• Imaging: Chest X-ray, pelvic and abdominal ultrasound, pelvic NMR and CT of the lungs and abdomen; (PET/CT if possible)• Cystoscopy, rectoscopy, IVU or sonographic renal examination
Recommended follow-upEvery 3 months for two years or more often if clinically indicated. Every 4-6 months thereafter. Annually afterwards. Investigations in addition to gynaecological examination should be performed depending on symptoms, local findings and general condition of the patient
Lungs & abdominal CT
Pelvic recurrence Extrapelvic recurrence
Options include:• Palliative radiotherapy or chemo-radiation• Systemic therapy• Supportive care
* Resection in selected cases(in particular paraaortic nodes)may be considered
Previous radiationNo previous radiation
Options include:• Chemo-radiation• Neoadjuvant chemotherapy (NACT)• Supportive care
Central pelvicrecurrence
Sidewall pelvicrecurrence
Options include • Radical hysterectomy in tumor <2 cm • Pelvic exenteration • Neoadjuvant chemotherapy (NACT) + surgeryOther options if surgery is not possible: • Re-irradiation • Neoadjuvant chemotherapy (NACT) + radiation • Systemic therapy • Supportive care
Options include: • Resection of isolated disease • Systemic therapy • Supportive care
Cervical cancer- recurrence -
Recommended work-upNeccessary investigations:• Vaginal and rectal examination, colposcopy, biopsy and/or endocervical curettage (ECC); conization or loop electrosurgical procedure (LEEP) if needed for definitive diagnosis• Histopathological finding with all standard tumor parameters• Laboratory analyses: WBC, biochemical analyses including including check for renal function and Hb • Imaging: Chest X-ray, abdominal and pelvic ultrasound (size and position of the tumor and tumor volume/cervix ratio)
Optional investigations:• Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should be confi rmed histologically
*Stage of the disease is determined using FIGO classification1
Recommended follow-upEvery 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination should be performed depending on symptoms, local findings and general condition of the patient
FIGO Ia FIGO Ib-IIa FIGO IIb-IV
• Diagnosis is based on conization; resection margins should be clear• Further decision depends on the presence of poor histologic prognostic factors2
Surgery Chemo-radiation Concomitant chemoradiationor Radical radiation only if unfit for chemotherapy
* Stage IV1 with vesicovaginal fistula: if pelvic, abdominal and chest CT exclude distant metastases, primary pelvic exenteration can be considered
• Medical contra-indications for surgery• Ib2/IIa tumors • Anterior vaginal extension• Invasive cancer after simple hysterectomy• Choice of the patient
• Radical hysterectomy (type C6)or • Radical trachelectomyor • Resection of the upper part of vagina and parametrectomy in case of previous simple hysterectomy and • Pelvic lymphadenectomy* Decision about further therapy is based on the presence of adverse histological factors
Neoadjuvant chemotherapy followed by radiation or surgery is an option for locally advanced tumors, but awaits confirmatory evidence from controlled clinical trials.
FIGO Ia1LVSI negative
• Conization/radical trachelectomyor • Modified radical hysterectomy(type B6)and • Pelvic Lymphadenectomy
• Conizationor • Simple hysterectomy (type A6)
Follow-up No adverse prognostic factors Adverse prognostic factors4 present
Follow-up Adjuvant therapy(Radiation ± Chemotherapy)
FIGO Ia1, LVSI positive
or
Cervical cancerSquamocellular, Adenocarcinoma,
Adenosquamous
Why are YOU here ???
Why am I here ???
Why are WE here ???